Titre : Villes

Villes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Villes : Questions médicales les plus fréquentes", "headline": "Villes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Villes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-31", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Villes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Régions géographiques", "url": "https://questionsmedicales.fr/mesh/D005842", "about": { "@type": "MedicalCondition", "name": "Régions géographiques", "code": { "@type": "MedicalCode", "code": "D005842", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Baltimore", "alternateName": "Baltimore", "url": "https://questionsmedicales.fr/mesh/D015142", "about": { "@type": "MedicalCondition", "name": "Baltimore", "code": { "@type": "MedicalCode", "code": "D015142", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.100" } } }, { "@type": "MedicalWebPage", "name": "Pékin", "alternateName": "Beijing", "url": "https://questionsmedicales.fr/mesh/D000068476", "about": { "@type": "MedicalCondition", "name": "Pékin", "code": { "@type": "MedicalCode", "code": "D000068476", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.114" } } }, { "@type": "MedicalWebPage", "name": "Boston", "alternateName": "Boston", "url": "https://questionsmedicales.fr/mesh/D001900", "about": { "@type": "MedicalCondition", "name": "Boston", "code": { "@type": "MedicalCode", "code": "D001900", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.210" } } }, { "@type": "MedicalWebPage", "name": "Chicago", "alternateName": "Chicago", "url": "https://questionsmedicales.fr/mesh/D002641", "about": { "@type": "MedicalCondition", "name": "Chicago", "code": { "@type": "MedicalCode", "code": "D002641", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.305" } } }, { "@type": "MedicalWebPage", "name": "District de Columbia", "alternateName": "District of Columbia", "url": "https://questionsmedicales.fr/mesh/D004219", "about": { "@type": "MedicalCondition", "name": "District de Columbia", "code": { "@type": "MedicalCode", "code": "D004219", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.429" } } }, { "@type": "MedicalWebPage", "name": "Los Angeles", "alternateName": "Los Angeles", "url": "https://questionsmedicales.fr/mesh/D015141", "about": { "@type": "MedicalCondition", "name": "Los Angeles", "code": { "@type": "MedicalCode", "code": "D015141", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.565" } } }, { "@type": "MedicalWebPage", "name": "Nouvelle-Orléans", "alternateName": "New Orleans", "url": "https://questionsmedicales.fr/mesh/D055820", "about": { "@type": "MedicalCondition", "name": "Nouvelle-Orléans", "code": { "@type": "MedicalCode", "code": "D055820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.697" } } }, { "@type": "MedicalWebPage", "name": "New York (ville)", "alternateName": "New York City", "url": "https://questionsmedicales.fr/mesh/D009519", "about": { "@type": "MedicalCondition", "name": "New York (ville)", "code": { "@type": "MedicalCode", "code": "D009519", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.741" } } }, { "@type": "MedicalWebPage", "name": "Philadelphie", "alternateName": "Philadelphia", "url": "https://questionsmedicales.fr/mesh/D015143", "about": { "@type": "MedicalCondition", "name": "Philadelphie", "code": { "@type": "MedicalCode", "code": "D015143", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.820" } } }, { "@type": "MedicalWebPage", "name": "San Francisco", "alternateName": "San Francisco", "url": "https://questionsmedicales.fr/mesh/D012495", "about": { "@type": "MedicalCondition", "name": "San Francisco", "code": { "@type": "MedicalCode", "code": "D012495", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.875" } } }, { "@type": "MedicalWebPage", "name": "Séoul", "alternateName": "Seoul", "url": "https://questionsmedicales.fr/mesh/D066106", "about": { "@type": "MedicalCondition", "name": "Séoul", "code": { "@type": "MedicalCode", "code": "D066106", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.887" } } }, { "@type": "MedicalWebPage", "name": "Tokyo", "alternateName": "Tokyo", "url": "https://questionsmedicales.fr/mesh/D014041", "about": { "@type": "MedicalCondition", "name": "Tokyo", "code": { "@type": "MedicalCode", "code": "D014041", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Villes", "alternateName": "Cities", "code": { "@type": "MedicalCode", "code": "D002947", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Divya Seth", "url": "https://questionsmedicales.fr/author/Divya%20Seth", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor, Pediatric Specialty Building, Detroit, MI 48201, USA. Electronic address: dseth@dmc.org." } }, { "@type": "Person", "name": "Shweta Saini", "url": "https://questionsmedicales.fr/author/Shweta%20Saini", "affiliation": { "@type": "Organization", "name": "Division of Hospital Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Pavadee Poowuttikul", "url": "https://questionsmedicales.fr/author/Pavadee%20Poowuttikul", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Marc Barthelemy", "url": "https://questionsmedicales.fr/author/Marc%20Barthelemy", "affiliation": { "@type": "Organization", "name": "Université Paris-Saclay, CEA, CNRS, Institut de Physique Théorique, 91191 Gif-sur-Yvette, France." } }, { "@type": "Person", "name": "Sasha Khomenko", "url": "https://questionsmedicales.fr/author/Sasha%20Khomenko", "affiliation": { "@type": "Organization", "name": "Institute for Global Health, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Structural and vascular changes in glaucoma with single-hemifield defect: predictors of opposite hemifield visual field progression.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36662236", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00417-023-05974-w" } }, { "@type": "ScholarlyArticle", "name": "Machine-Identified Patterns of Visual Field Loss and an Association with Rapid Progression in the Ocular Hypertension Treatment Study.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35817199", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ophtha.2022.07.001" } }, { "@type": "ScholarlyArticle", "name": "Association of baseline optical coherence tomography angiography with the development of glaucomatous visual field defects in preperimetric glaucoma eyes.", "datePublished": "2022-08-05", "url": "https://questionsmedicales.fr/article/37863500", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bjo-2021-321025" } }, { "@type": "ScholarlyArticle", "name": "Frequency of Visual Fields Needed to Detect Glaucoma Progression: A Computer Simulation Using Linear Mixed Effects Model.", "datePublished": "2023-03-30", "url": "https://questionsmedicales.fr/article/37054400", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002155" } }, { "@type": "ScholarlyArticle", "name": "Investigating the linkage between mesopic spatial summation and variations in retinal ganglion cell density across the central visual field.", "datePublished": "2023-04-28", "url": "https://questionsmedicales.fr/article/37118942", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/opo.13158" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Villes", "item": "https://questionsmedicales.fr/mesh/D002947" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Villes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Villes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Villes", "description": "Comment évaluer l'impact de la pollution urbaine sur la santé ?\nQuels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?\nComment identifier les zones à risque sanitaire en ville ?\nQuels indicateurs de santé sont pertinents en milieu urbain ?\nComment évaluer l'accès aux soins en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=7#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Villes", "description": "Quels symptômes sont liés à la pollution de l'air ?\nComment la vie urbaine affecte-t-elle la santé mentale ?\nQuels symptômes sont associés à la chaleur urbaine ?\nQuels signes indiquent une mauvaise qualité de l'eau en ville ?\nQuels symptômes sont liés à l'isolement social en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=7#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Villes", "description": "Comment prévenir les maladies liées à la pollution en ville ?\nQuelles mesures peuvent réduire le stress urbain ?\nComment améliorer la qualité de l'eau en milieu urbain ?\nQuelles stratégies aident à prévenir les coups de chaleur ?\nComment favoriser la santé mentale en milieu urbain ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=7#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Villes", "description": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?\nComment traiter les effets de la chaleur extrême en ville ?\nQuels traitements sont disponibles pour le stress urbain ?\nComment traiter les maladies liées à l'eau contaminée ?\nQuels traitements sont recommandés pour l'anxiété urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=7#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Villes", "description": "Quelles complications peuvent survenir à cause de la pollution ?\nQuels risques de santé sont liés à l'isolement social ?\nQuelles complications peuvent résulter de la chaleur extrême ?\nComment la qualité de l'eau affecte-t-elle la santé ?\nQuelles complications sont liées à la vie urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=7#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Villes", "description": "Quels facteurs de risque sont associés à la pollution urbaine ?\nComment le stress urbain influence-t-il la santé ?\nQuels sont les risques liés à la chaleur en milieu urbain ?\nQuels facteurs augmentent le risque de maladies infectieuses en ville ?\nQuels comportements augmentent le risque de problèmes de santé en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=7#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact de la pollution urbaine sur la santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact se mesure par des études épidémiologiques et des indicateurs de santé." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de laboratoire, des examens cliniques et des enquêtes de santé sont utilisés." } }, { "@type": "Question", "name": "Comment identifier les zones à risque sanitaire en ville ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse géospatiale et les données de santé publique aident à identifier ces zones." } }, { "@type": "Question", "name": "Quels indicateurs de santé sont pertinents en milieu urbain ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les taux de maladies respiratoires, cardiovasculaires et d'obésité sont des indicateurs clés." } }, { "@type": "Question", "name": "Comment évaluer l'accès aux soins en ville ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'accès se mesure par la distance aux établissements de santé et la disponibilité des services." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la pollution de l'air ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent toux, essoufflement, irritation des yeux et fatigue." } }, { "@type": "Question", "name": "Comment la vie urbaine affecte-t-elle la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'anxiété et la dépression sont souvent exacerbés par la vie urbaine." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la chaleur urbaine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent déshydratation, épuisement et coups de chaleur." } }, { "@type": "Question", "name": "Quels signes indiquent une mauvaise qualité de l'eau en ville ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent des maladies gastro-intestinales et des éruptions cutanées." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'isolement social en ville ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des symptômes de dépression et d'anxiété." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à la pollution en ville ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des politiques de réduction de la pollution et des campagnes de sensibilisation sont essentielles." } }, { "@type": "Question", "name": "Quelles mesures peuvent réduire le stress urbain ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des espaces verts et des activités communautaires aide à réduire le stress." } }, { "@type": "Question", "name": "Comment améliorer la qualité de l'eau en milieu urbain ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de filtration et des contrôles réguliers de la qualité de l'eau sont nécessaires." } }, { "@type": "Question", "name": "Quelles stratégies aident à prévenir les coups de chaleur ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Éduquer sur l'hydratation et l'ombre, et créer des refuges frais sont des stratégies clés." } }, { "@type": "Question", "name": "Comment favoriser la santé mentale en milieu urbain ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Encourager le soutien social et l'accès à des services de santé mentale est crucial." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les bronchodilatateurs, corticostéroïdes et thérapies respiratoires sont courants." } }, { "@type": "Question", "name": "Comment traiter les effets de la chaleur extrême en ville ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, le repos et, si nécessaire, des soins médicaux." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le stress urbain ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie cognitivo-comportementale et les médicaments peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "Comment traiter les maladies liées à l'eau contaminée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, des antibiotiques et des soins symptomatiques." } }, { "@type": "Question", "name": "Quels traitements sont recommandés pour l'anxiété urbaine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies psychologiques et les médicaments anxiolytiques sont souvent prescrits." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir à cause de la pollution ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies respiratoires chroniques et des cancers." } }, { "@type": "Question", "name": "Quels risques de santé sont liés à l'isolement social ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des maladies cardiovasculaires et des troubles mentaux." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de la chaleur extrême ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des coups de chaleur, des déshydratations sévères et des décès." } }, { "@type": "Question", "name": "Comment la qualité de l'eau affecte-t-elle la santé ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise qualité de l'eau peut entraîner des infections et des maladies gastro-intestinales." } }, { "@type": "Question", "name": "Quelles complications sont liées à la vie urbaine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anxiété, la dépression et des maladies chroniques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à la pollution urbaine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'industrialisation, le trafic routier et l'urbanisation rapide." } }, { "@type": "Question", "name": "Comment le stress urbain influence-t-il la santé ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver des conditions comme l'hypertension et l'anxiété." } }, { "@type": "Question", "name": "Quels sont les risques liés à la chaleur en milieu urbain ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des maladies chroniques sont particulièrement à risque." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies infectieuses en ville ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "La densité de population et l'accès limité à l'eau potable augmentent les risques." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque de problèmes de santé en ville ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, la sédentarité et une alimentation déséquilibrée sont des comportements à risque." } } ] } ] }

Sources (10000 au total)

Structural and vascular changes in glaucoma with single-hemifield defect: predictors of opposite hemifield visual field progression.

To investigate longitudinal changes in optic nerve head (ONH) superficial vessel density (VD), macular VD, circumpapillary retinal nerve fiber layer (RNFL) thickness, and macular ganglion cell-inner p... This retrospective observational study included 61 POAG eyes with VF defect confined to a single hemifield monitored over a mean follow-up time of 2.7 years. Development of VF defect in opposite hemif... Among 61 eyes, 17 eyes (27.9%) were classified as "conversion" and 44 eyes (72.1%) were classified as "non-conversion" groups. The conversion group exhibited significantly greater rates of both VD and... Monitoring progressive changes in VD and structural parameters effectively predict future VF defect in the opposite hemifields of POAG eyes with single-hemifield defects....

Machine-Identified Patterns of Visual Field Loss and an Association with Rapid Progression in the Ocular Hypertension Treatment Study.

To identify patterns of visual field (VF) loss based on unsupervised machine learning and to identify patterns that are associated with rapid progression.... Cross-sectional and longitudinal study.... A total of 2231 abnormal VFs from 205 eyes of 176 Ocular Hypertension Treatment Study (OHTS) participants followed over approximately 16 years.... Visual fields were assessed by an unsupervised deep archetypal analysis algorithm and an OHTS-certified VF reader to identify prevalent patterns of VF loss. Machine-identified patterns of glaucoma dam... Machine-expert correspondence and type of patterns of VF loss associated with rapid progression.... The average VF mean deviation (MD) at conversion to glaucoma was -2.7 decibels (dB) (standard deviation [SD] = 2.4 dB), whereas the average MD of the eyes at the last visit was -5.2 dB (SD = 5.5 dB). ... An automated machine learning system can identify patterns of VF loss and could provide objective and reproducible nomenclature for characterizing early signs of visual defects and rapid progression i...

Association of baseline optical coherence tomography angiography with the development of glaucomatous visual field defects in preperimetric glaucoma eyes.

To evaluate whether baseline vessel density (VD) parameters derived from optical coherence tomography angiography (OCT-A) is associated with the development of glaucomatous visual field (VF) defects i... One eye from each of 200 consecutive PPG patients with a normal standard automated perimetry and OCT-A at baseline was retrospectively analysed. OCT-A was used to measure the circumpapillary VD (cpVD)... During a 3.1-year average follow-up period, 18 eyes (9.0%) developed glaucomatous VF defects. At baseline, the lower inferior temporal cpVD (HR (95% CI)=0.934 (0.883 to 0.988); p=0.017) and thinner in... In PPG eyes, a lower baseline inferior temporal cpVD is significantly associated with glaucomatous VF defect development and a faster rate of global VF loss....

Frequency of Visual Fields Needed to Detect Glaucoma Progression: A Computer Simulation Using Linear Mixed Effects Model.

Irregular visual field test frequency at relatively short intervals initially and longer intervals later on in the disease provided acceptable results in detecting glaucoma progression.... It is challenging to maintain a balance between the frequency of visual field testing and the long-term costs that may result from insufficient treatment of glaucoma patients. This study aims to simul... An LMM with random intercept and slope was used to simulate the series of mean deviation sensitivities over time. A cohort study including 277 glaucoma eyes that were followed for 9.0±1.2 years was us... By doing one confirmatory test, the percentage of incorrect progression detection decreased considerably. The time to detect progression was shorter for eyes with an evenly spaced 4-monthly schedule, ... Irregular visual field test frequency at relatively short intervals initially and longer intervals later on in the disease provided acceptable results in detecting glaucoma progression. This approach ...

Investigating the linkage between mesopic spatial summation and variations in retinal ganglion cell density across the central visual field.

The relationship between perimetric stimulus area and Ricco's area (RA) determines measured thresholds and the sensitivity of perimetry to retinal disease. The nature of this relationship, in addition... Achromatic luminance thresholds were measured for six incremental spot stimuli (0.009-2.07 deg... Ricco's area exhibited a small but statistically insignificant increase between 2.5° and 10° eccentricity. Compared with photopic conditions, RA was larger, with the difference between RA and the Gold... Ricco's area and the number of RGCs underlying RA do not vary significantly across the central visual field in mesopic conditions. However, RA is larger and more similar to the standard perimetric Gol...

Bidirectional gated recurrent unit network model can generate future visual field with variable number of input elements.

This study aimed to predict future visual field tests using a bidirectional gated recurrent unit (Bi-GRU) and assess its performance based on the number of input visual field tests and the prediction ... This study included patients who underwent visual field tests at least four times at five university hospitals between June 2004 and April 2022. All data were accessed in October 2022 for research pur... The prediction errors of the Bi-GRU model for MD, PSD, VFI, and TDV ranged from 1.20 to 1.68 dB, 0.95 to 1.16 dB, 3.64 to 4.51%, and 2.13 to 2.60 dB, respectively, depending on the number of input vis... In clinical practice, the Bi-GRU model can predict future visual field tests at the desired time points using three or more previous visual field tests....

Combining Optical Coherence Tomography and Optical Coherence Tomography Angiography Longitudinal Data for the Detection of Visual Field Progression in Glaucoma.

To use longitudinal optical coherence tomography (OCT) and OCT angiography (OCTA) data to detect glaucomatous visual field (VF) progression with a supervised machine learning approach.... Prospective cohort study.... One hundred ten eyes of patients with suspected glaucoma (33.6%) and patients with glaucoma (66.4%) with a minimum of 5 24-2 VF tests and 3 optic nerve head and macula images over an average follow-up... VF progression was detected in 28 eyes (25.5%). The model with combined baseline and longitudinal OCT and OCTA parameters at the global and hemifield levels had the best classification accuracy to det... Longitudinal OCTA measurements complement OCT-derived structural metrics for the evaluation of functional VF loss in patients with glaucoma....

Associations of long-term fluctuation in blood pressure and ocular perfusion pressure with visual field progression in normal-tension glaucoma.

The aim of this study was to investigate the associations between fluctuation in blood pressure (BP), ocular perfusion pressure (OPP) and visual field (VF) progression in normal-tension glaucoma (NTG)... This prospective, longitudinal study included 44 patients with NTG. Only newly diagnosed NTG patients who had not been treated with a glaucoma medication were included. Patients were examined every ye... After 7 years of follow-up, 9 of the 44 patients showed VF progression. The standard deviation (SD) of SBP and OPP were significantly associated with VF progression (P = 0.007, < 0.001, respectively).... Fluctuation in OPP was associated with VF progression in patients with NTG....

Differing Associations between Optic Nerve Head Strains and Visual Field Loss in Patients with Normal- and High-Tension Glaucoma.

To study the associations between optic nerve head (ONH) strains under intraocular pressure (IOP) elevation with retinal sensitivity in patients with glaucoma.... Clinic-based cross-sectional study.... Two hundred twenty-nine patients with primary open-angle glaucoma (subdivided into 115 patients with high-tension glaucoma [HTG] and 114 patients with normal-tension glaucoma [NTG]).... For 1 eye of each patient, we imaged the ONH using spectral-domain OCT under the following conditions: (1) primary gaze and (2) primary gaze with acute IOP elevation (to approximately 35 mmHg) achieve... Associations between ONH strains and values of retinal sensitivity from visual field testing.... For patients with HTG, we found (1) significant negative linear associations between ONH strains and retinal sensitivity (P < 0.001; on average, a 1% increase in ONH strains corresponded to a decrease... We found significant negative associations between IOP-induced ONH strains and retinal sensitivity in a relatively large glaucoma cohort. Specifically, patients with HTG who experienced higher ONH str...